Sabine Yerly
Geneve, GE, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 150 publications
Sustained Virologic Suppression After Discontinuation of Long-acting Cabotegravir/Rilpivirine: A Two-case Series Highlighting Unexpected Heterogeneity in Pharmacokinetics and Viral Control.
Journal: Open forum infectious diseases
Published: April 08, 2026
Pretreatment Resistance to Integrase Inhibitors in the Swiss HIV Cohort Study From 1995 to 2025.
Journal: Open forum infectious diseases
Published: April 07, 2026
Similar Changes in Proviral Landscapes Over 10 Years in 40 Individuals With Diverging HIV Reservoir Dynamics and Viral Load Kinetics.
Journal: Open forum infectious diseases
Published: December 04, 2025
Pretransplant CMV-IgG Titers and DNAemia Are Associated With CMV Infections Post Allogeneic Hematopoietic Cell Transplant With or Without Letermovir.
Journal: Open forum infectious diseases
Published: September 10, 2025
Dolutegravir Resistance in Mozambique: Insights from a Programmatic HIV Resistance Testing Intervention in a Highly Antiretroviral Therapy-Experienced Cohort.
Journal: Infectious disease reports
Published: June 25, 2025
Acute airway compromise in a patient with long-lasting dyspnea.
Journal: European annals of otorhinolaryngology, head and neck diseases
Published: January 25, 2025
Major role of dolutegravir in the emergence of the S147G integrase resistance mutation.
Journal: The Journal of antimicrobial chemotherapy
Published: October 14, 2024
Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development.
Journal: Cell host & microbe
Published: September 10, 2024
Performance of the cobas EBV and cobas BKV assays: multi-site comparison of standardized quantitation.
Journal: Journal of clinical microbiology
Published: July 24, 2024
Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.
Journal: Open forum infectious diseases
Published: May 31, 2024
Last Updated: 09/26/2026